Expert Experience with Aqumeldi®
Can you tell us about your experience using Aqumeldi®
in your paediatric heart failure patients?
This content is intended for UK & ROI healthcare professionals. Not a healthcare professional? Return to audience selector.
This content reflects expert opinion. Certain elements are based on professional judgment and personal interpretation informed by clinical experience and expertise.
Can you tell us about your experience using Aqumeldi®
in your paediatric heart failure patients?
Thinking about your introduction to Aqumeldi® and the LENA studies, what specific data has stood out to you as a clinician and why?
With Aqumeldi® being the only licensed ACEI for use in paediatric HF (since it's launch), how has this changed your prescribing/ treatment practise?
Can you briefly tell us about how you developed the paediatric HF ACEI guidelines at your trust and since its implementation, how this has changed clinical practice?
Considering the guidelines, could you share with us some patient cases regarding ACEI initiation?
Considering the guidelines, could you share with us some patient cases regarding ACEI initiation?
Can you tell us about your clinical practice with Aqumeldi® regarding the once or twice daily dosing preference?
What feedback have you had from parents/ carers of children using Aqumeldi®?
How would you describe your multidisciplinary team's experience with Aqumeldi®?
UK-ENA-26-0007 | April 2026
Adverse Event Reporting Information
UK: Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
Republic of Ireland: Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.
Adverse events should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com